Nasdaq:US$13.18 (-0.15) | HKEX:HK$20.30 (-0.52) | AIM:£2.00 (-0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)